Here are the 424B prospectus supplements from Dare Bioscience, Inc. (DARE) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow DARE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DARE filings page.
Daré Bioscience, Inc. (DARE) has filed a resale prospectus covering up to 8,934,345 shares of common stock for selling stockholders. This includes 8,759,162 shares issuable upon exercise of Series A and Series B common warrants and 175,183 shares issuable upon exercise of placement agent warrants. Daré is not selling shares and will not receive proceeds from stockholder resales, but may receive up to approximately $12.4 million if all warrants are exercised for cash at exercise prices of $1.37 and $2.1235 per share.
The warrants were issued in an August 2026 financing that combined a registered direct offering with a concurrent private placement and are exercisable only after required Nasdaq stockholder approval, with built-in beneficial ownership limits of 4.99% or 9.99%. Shares outstanding were 19,669,083 as of August 20, 2026; this is a baseline figure, not the amount being offered. Daré highlights a women’s health–focused pipeline, a new Section 503B compounding and consumer health strategy, substantial ongoing capital needs, a prior going-concern emphasis in its 2025 audit report, and continued risk around maintaining its Nasdaq Capital Market listing pending a panel decision.
Daré Bioscience, Inc. is conducting a primary shelf takedown offering of 4,085,687 shares of common stock and 293,894 pre-funded warrants at $1.37 per share and $1.3699 per pre-funded warrant, for gross proceeds of $5,999,996.58 and estimated net proceeds of about $5.4 million.
Each pre-funded warrant is immediately exercisable for one share at $0.0001 and is subject to a 4.99% (or 9.99%) beneficial ownership limitation. In a concurrent private placement, Daré is issuing Series A and B warrants to purchase up to 8,759,162 additional shares and/or pre-funded warrants, exercisable only if stockholders approve under Nasdaq rules.
Common shares outstanding will increase to about 19.4 million (or 19.7 million if all pre-funded warrants are exercised). The company plans to use net proceeds for working capital and general corporate purposes, including its 503B compounding and consumer health strategies and R&D, amid disclosed going-concern and Nasdaq listing risks.